A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

September 6, 2017

Study Completion Date

September 6, 2017

Conditions

Healthy Volunteers

Interventions

DRUG

Ipatasertib

Ipatasertib 100 mg tablet orally once daily.

DRUG

Itraconazole

Itraconazole 100 mg capsules orally once daily.

Trial Locations (1)

Covance Research Unit - Dallas, Dallas

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT03222310 - A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib | Biotech Hunter | Biotech Hunter